SV2002000204A - Metodos para usar 22045, una fosfodiesterasa humana de nucleotidos ciclicos - Google Patents
Metodos para usar 22045, una fosfodiesterasa humana de nucleotidos ciclicosInfo
- Publication number
- SV2002000204A SV2002000204A SV2000000204A SV2000000204A SV2002000204A SV 2002000204 A SV2002000204 A SV 2002000204A SV 2000000204 A SV2000000204 A SV 2000000204A SV 2000000204 A SV2000000204 A SV 2000000204A SV 2002000204 A SV2002000204 A SV 2002000204A
- Authority
- SV
- El Salvador
- Prior art keywords
- methods
- phosphodesterase
- phosphodiesterase
- polynucleotides
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Cardiology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
METODOS PARA USAR UNA FOSFODIESTERASA HUMANA DE NUCLEOTIDOS CICLICOS QUE PERTENECEN A LA SUPERFAMILIA DE LAS FOSFODIESTERASA DE MAMIFEROS.LA INVENCION SE RELACIONA TAMBIEN CON METODOS PARA USAR LOS POLINUCLEICOS QUE CODIFICAN LA FOSFODIESTERASA. LA INVENCION SE RELACIONA CON METODOS PARA USAR LOS POLIPEPTIDOS Y LOS POLINUCLEOTIDOS DE LA FOSFODIESTERASA COMO UN BLANCO PARA LA DIAGNOSIS Y EL TRATAMIENTO DE AFECCIONES MEDIADAS O RELACIONADAS CON LA FOSFODIESTERASA. LA INVENCION SE RELACIONA ADEMAS CON METODOS PARA EL ANALISIS DE DROGAS QUE USAN LOS POLIPEPTIDOS Y LOS POLINUCLEOTIDOS DE LA FOSFODIESTERASA PARA INDENTIFICAR AGONISTAS Y ANTAGONISTAS PARA DIAGNOSIS Y TRATAMIENTOS. LA INVENCION SE ABARCA ADEMAS AGONISTAS Y ANTAGONISTAS BASADOS EN LOS POLIPEPTIDOS Y EN LO POLINUCLEOTIDOS DE LA FOSFODIESTERASA. LA INVENCION SE RELACIONA ADEMAS CON AGONISTAS Y ANTAGONISTAS IDENTIFICADOS POR MEDIO DE LOS METODOS DE ANALISIS DE DROGAS CON LOS POLIPEPTIDOS Y LOS POLINUCLEOTIDOS DE LA FOSFODIESTERASA COMO BLANCO.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/420,190 US6673564B2 (en) | 1999-10-18 | 1999-10-18 | Methods for using 22045, a human cyclic nucleotide phosphodiesterase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SV2002000204A true SV2002000204A (es) | 2002-09-12 |
Family
ID=23665445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SV2000000204A SV2002000204A (es) | 1999-10-18 | 2000-10-18 | Metodos para usar 22045, una fosfodiesterasa humana de nucleotidos ciclicos |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6673564B2 (es) |
| EP (1) | EP1224268A1 (es) |
| JP (1) | JP2003512049A (es) |
| AU (1) | AU8028900A (es) |
| CO (1) | CO5280155A1 (es) |
| DO (1) | DOP2000000081A (es) |
| GT (1) | GT200000181A (es) |
| PE (1) | PE20010808A1 (es) |
| SV (1) | SV2002000204A (es) |
| WO (1) | WO2001029199A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7745142B2 (en) * | 1997-09-15 | 2010-06-29 | Molecular Devices Corporation | Molecular modification assays |
| US7632651B2 (en) | 1997-09-15 | 2009-12-15 | Mds Analytical Technologies (Us) Inc. | Molecular modification assays |
| JP2001302667A (ja) * | 2000-04-28 | 2001-10-31 | Bayer Ag | イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体 |
| US6930114B2 (en) | 2000-12-13 | 2005-08-16 | Bayer Pharmaceuticals Corporation | Pyrrolo (2.1a)dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors |
| CN101259120B (zh) | 2002-03-04 | 2012-07-04 | Hdac默克研究有限责任公司 | 辛二酰苯胺异羟肟酸或其可药用盐在制备诱导末期分化的药物的用途 |
| US7456219B2 (en) | 2002-03-04 | 2008-11-25 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
| AU2002953285A0 (en) * | 2002-12-12 | 2003-01-02 | Protech Research Pty Ltd | Yeast treatment |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5798246A (en) * | 1996-03-25 | 1998-08-25 | Incyte Pharmaceuticals, Inc. | Cyclic nucleotide phosphodiesterase |
| US5858694A (en) * | 1997-05-30 | 1999-01-12 | Cell Pathways, Inc. | Method for identifying compounds for inhibition of cancerous lesions |
| US5932465A (en) * | 1997-10-16 | 1999-08-03 | Icos Corporation | Phosphodiesterase 8A |
| IL137164A0 (en) * | 1998-01-23 | 2001-07-24 | Newbiotics Inc | Enzyme catalyzed therapeutic agents |
| US6114111A (en) * | 1998-03-30 | 2000-09-05 | Rigel Pharmaceuticals, Inc. | Mammalian protein interaction cloning system |
| EP0967284A1 (en) | 1998-05-28 | 1999-12-29 | Pfizer Limited | Phosphodiesterases |
| US6100037A (en) * | 1999-01-07 | 2000-08-08 | Incyte Pharmaceuticals, Inc. | Human cyclic nucleotide PDEs |
-
1999
- 1999-10-18 US US09/420,190 patent/US6673564B2/en not_active Expired - Fee Related
-
2000
- 2000-10-18 AU AU80289/00A patent/AU8028900A/en not_active Abandoned
- 2000-10-18 DO DO2000000081A patent/DOP2000000081A/es unknown
- 2000-10-18 GT GT200000181A patent/GT200000181A/es unknown
- 2000-10-18 WO PCT/US2000/028806 patent/WO2001029199A1/en not_active Ceased
- 2000-10-18 EP EP00970987A patent/EP1224268A1/en not_active Withdrawn
- 2000-10-18 SV SV2000000204A patent/SV2002000204A/es unknown
- 2000-10-18 CO CO00079327A patent/CO5280155A1/es not_active Application Discontinuation
- 2000-10-18 PE PE2000001112A patent/PE20010808A1/es not_active Application Discontinuation
- 2000-10-18 JP JP2001532184A patent/JP2003512049A/ja active Pending
-
2003
- 2003-06-11 US US10/458,839 patent/US20030215898A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU8028900A (en) | 2001-04-30 |
| PE20010808A1 (es) | 2001-08-22 |
| CO5280155A1 (es) | 2003-05-30 |
| JP2003512049A (ja) | 2003-04-02 |
| US20020081633A1 (en) | 2002-06-27 |
| DOP2000000081A (es) | 2002-09-16 |
| EP1224268A1 (en) | 2002-07-24 |
| GT200000181A (es) | 2002-04-11 |
| US20030215898A1 (en) | 2003-11-20 |
| US6673564B2 (en) | 2004-01-06 |
| WO2001029199A1 (en) | 2001-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0309665A (pt) | Tratamento de deficiência de alfa-galactosidase a | |
| AR008444A1 (es) | Empleo de antagonistas de leptina para el tratamiento de la resistencia a la insulina en diabetes del tipo ii | |
| BRPI0519241A2 (pt) | agonistas, composiÇÕes, mÉtodos e usos de glp-1 | |
| EA200401284A1 (ru) | Замещённые бензазолы и их применение в качестве ингибиторов киназы raf | |
| BR9913932A (pt) | Uso de análogos de glp-1 no tratamento de derrame | |
| ATE365213T1 (de) | Aminosäuresequenzen die die fähigkeit besitzen, die durchdringung durch eine biologische barriere erleichtern | |
| UY30015A1 (es) | Combinación de antagonista de actividad biológica de angiopoyetina-2 y antagonista de actividad biológica de vegf-a y/o kdr y/o flt1, composiciones farmacéuticas y aplicaciones | |
| BR0111125A (pt) | Moléculas de ácido nucléico de nrg-2, polipeptìdeos, e métodos diagnóstico e terapêuticos | |
| UY27939A1 (es) | Compuestos | |
| BR0307508A (pt) | Composto, composição farmacêutica, e, métodos de tratamento ou prevenção de dor e inflamação e de tratamento de doença | |
| PT1052905E (pt) | Processo anti-germinativo de tuberculos e bolbos utilizando o eugenol e/ou o isoeugenol | |
| ATE360077T1 (de) | 22025, eine neue menschliche zyklische nukleotiden phosphodiesterase | |
| BR0313239A (pt) | Composto, composição farmacêutica, e, métodos de tratamento ou prevenção de dor e inflamação e de doenças | |
| EA200601074A1 (ru) | Применение производных пептидов для лечения болей, связанных с заболеванием центральной нервной системы (центральной невропатической боли) | |
| AR030554A1 (es) | Moleculas similares a receptores il-17 y usos de las mismas | |
| ATE356994T1 (de) | Screeningverfahren mit pim1-kinase oder pim3- kinase | |
| SV2002000204A (es) | Metodos para usar 22045, una fosfodiesterasa humana de nucleotidos ciclicos | |
| BRPI0409359A (pt) | análogos quiméricos de somatostatina-dopamina | |
| SI1276476T1 (sl) | Uporaba bradikardnih snovi pri zdravljenju miokardnih bolezni, povezanih s hipertrofijo, in nove kombinacije zdravil | |
| DK1397681T3 (da) | Fremgangsmåde til identificering af midler til behandling af diabetes | |
| EA200400399A1 (ru) | Способы лечения легочных заболеваний | |
| BRPI0411324A (pt) | composições farmacêuticas e métodos de tratamento de resposta mediada por histamina em pacientes | |
| DE60115349D1 (de) | Polymorphismen im Gen für den humanen organischen Anionentransporter C (OATP-C) | |
| ES2059457T3 (es) | Utilizacion de bezafibrato para el tratamiento de la diabetes. | |
| MX9403032A (es) | Quinolil-dihidropiridinas condensadas, procedimiento para su fabricacion ysu uso en medicamentos. |